A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma

A Children's Oncology Group study

Terzah M. Horton, Richard A. Drachtman, Lu Chen, Peter D. Cole, Kathleen Mccarten, Stephan Voss, Robert P. Guillerman, Allen Buxton, Scott C. Howard, Shirley M. Hogan, Andrea M. Sheehan, Dolores López-Terrada, Matthew D. Mrazek, Neeraj Agrawal, Meng Fen Wu, Hao Liu, Pedro A. De Alarcon, Tanya M. Trippet, Cindy L. Schwartz

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval (CI): 59-83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61-95%; p = 0·32). Although not statistically different, results suggest IVB may be a promising combination.

Original languageEnglish (US)
Pages (from-to)118-122
Number of pages5
JournalBritish Journal of Haematology
Volume170
Issue number1
DOIs
StatePublished - Jul 1 2015

Fingerprint

Ifosfamide
Hodgkin Disease
Young Adult
Confidence Intervals
Pediatrics
Clinical Trials
Bortezomib
vinorelbine

Keywords

  • Childhood haematological malignancies
  • Clinical trials
  • NF-κB
  • Paediatric oncology

ASJC Scopus subject areas

  • Hematology

Cite this

A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma : A Children's Oncology Group study. / Horton, Terzah M.; Drachtman, Richard A.; Chen, Lu; Cole, Peter D.; Mccarten, Kathleen; Voss, Stephan; Guillerman, Robert P.; Buxton, Allen; Howard, Scott C.; Hogan, Shirley M.; Sheehan, Andrea M.; López-Terrada, Dolores; Mrazek, Matthew D.; Agrawal, Neeraj; Wu, Meng Fen; Liu, Hao; De Alarcon, Pedro A.; Trippet, Tanya M.; Schwartz, Cindy L.

In: British Journal of Haematology, Vol. 170, No. 1, 01.07.2015, p. 118-122.

Research output: Contribution to journalArticle

Horton, TM, Drachtman, RA, Chen, L, Cole, PD, Mccarten, K, Voss, S, Guillerman, RP, Buxton, A, Howard, SC, Hogan, SM, Sheehan, AM, López-Terrada, D, Mrazek, MD, Agrawal, N, Wu, MF, Liu, H, De Alarcon, PA, Trippet, TM & Schwartz, CL 2015, 'A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: A Children's Oncology Group study', British Journal of Haematology, vol. 170, no. 1, pp. 118-122. https://doi.org/10.1111/bjh.13388
Horton, Terzah M. ; Drachtman, Richard A. ; Chen, Lu ; Cole, Peter D. ; Mccarten, Kathleen ; Voss, Stephan ; Guillerman, Robert P. ; Buxton, Allen ; Howard, Scott C. ; Hogan, Shirley M. ; Sheehan, Andrea M. ; López-Terrada, Dolores ; Mrazek, Matthew D. ; Agrawal, Neeraj ; Wu, Meng Fen ; Liu, Hao ; De Alarcon, Pedro A. ; Trippet, Tanya M. ; Schwartz, Cindy L. / A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma : A Children's Oncology Group study. In: British Journal of Haematology. 2015 ; Vol. 170, No. 1. pp. 118-122.
@article{4051b993f2b04647bc4a4a28fafef20d,
title = "A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: A Children's Oncology Group study",
abstract = "A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72{\%}; 95{\%} confidence interval (CI): 59-83{\%}]. Although few patients achieved the primary objective, OR with IVB improved to 83{\%} (95{\%} CI: 61-95{\%}; p = 0·32). Although not statistically different, results suggest IVB may be a promising combination.",
keywords = "Childhood haematological malignancies, Clinical trials, NF-κB, Paediatric oncology",
author = "Horton, {Terzah M.} and Drachtman, {Richard A.} and Lu Chen and Cole, {Peter D.} and Kathleen Mccarten and Stephan Voss and Guillerman, {Robert P.} and Allen Buxton and Howard, {Scott C.} and Hogan, {Shirley M.} and Sheehan, {Andrea M.} and Dolores L{\'o}pez-Terrada and Mrazek, {Matthew D.} and Neeraj Agrawal and Wu, {Meng Fen} and Hao Liu and {De Alarcon}, {Pedro A.} and Trippet, {Tanya M.} and Schwartz, {Cindy L.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1111/bjh.13388",
language = "English (US)",
volume = "170",
pages = "118--122",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma

T2 - A Children's Oncology Group study

AU - Horton, Terzah M.

AU - Drachtman, Richard A.

AU - Chen, Lu

AU - Cole, Peter D.

AU - Mccarten, Kathleen

AU - Voss, Stephan

AU - Guillerman, Robert P.

AU - Buxton, Allen

AU - Howard, Scott C.

AU - Hogan, Shirley M.

AU - Sheehan, Andrea M.

AU - López-Terrada, Dolores

AU - Mrazek, Matthew D.

AU - Agrawal, Neeraj

AU - Wu, Meng Fen

AU - Liu, Hao

AU - De Alarcon, Pedro A.

AU - Trippet, Tanya M.

AU - Schwartz, Cindy L.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval (CI): 59-83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61-95%; p = 0·32). Although not statistically different, results suggest IVB may be a promising combination.

AB - A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval (CI): 59-83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61-95%; p = 0·32). Although not statistically different, results suggest IVB may be a promising combination.

KW - Childhood haematological malignancies

KW - Clinical trials

KW - NF-κB

KW - Paediatric oncology

UR - http://www.scopus.com/inward/record.url?scp=84931563104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931563104&partnerID=8YFLogxK

U2 - 10.1111/bjh.13388

DO - 10.1111/bjh.13388

M3 - Article

VL - 170

SP - 118

EP - 122

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -